Hua Medicine (Shanghai) Ltd. (HKG:2552)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.340
+0.240 (7.74%)
Mar 10, 2026, 4:08 PM HKT
41.53%
Market Cap 3.06B
Revenue (ttm) 406.16M
Net Income (ttm) 1.18B
Shares Out 988.01M
EPS (ttm) 1.20
PE Ratio 2.59
Forward PE 3.44
Dividend n/a
Ex-Dividend Date n/a
Volume 17,480,000
Average Volume 3,099,500
Open 3.100
Previous Close 3.100
Day's Range 3.100 - 3.350
52-Week Range 1.730 - 4.950
Beta 1.11
RSI 55.63
Earnings Date Mar 27, 2026

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic diseas... [Read more]

Sector Healthcare
Founded 2011
Employees 285
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2552
Full Company Profile

Financial Performance

In 2024, Hua Medicine (Shanghai)'s revenue was 255.89 million, an increase of 234.02% compared to the previous year's 76.61 million. Losses were -250.14 million, 18.4% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.